Impiego di cellule staminali in terapia veterinaria

Over the past few years, in veterinary medicine there has been an increased interest in understanding the biology of mesenchymal stem cells (MSCs). This interest comes from their potential clinical use especially in wound repair, tissue engineering and application in therapeutics fields, including regenerative surgery. MSCs can be isolated directly from bone marrow aspirates, adipose tissue, umbilical cord and various foetal tissues. In this study, mesenchymal stem cells were isolated from equine bone marrow, adipose tissue, cord blood, Wharton’s Jelly and, for the first time, amniotic fluid. All these cell lines underwent in vitro differentiation in chondrocytes, osteocytes and adipocytes. After molecular characterization, cells resulted positive for mesenchymal markers such as CD90, CD105, CD44 and negative for CD45, CD14, CD34 and CD73. Adipose tissue and bone marrow mesenchymal stem cells were successfully applied in the treatment of tendinitis in race horses. Furthermore, for the first time in the horse, skin wounds of septicemic foal, were treated applying amniotic stem cells. Finally, results never reported have been obtained in the present study, isolating mesenchymal stem cells from domestic cat foetal fluid and membranes. All cell lines underwent in vitro differentiation and expressed mesenchymal molecular markers.

Fisiopatologia, clinica, storia naturale e terapia delle cardiomiopatie amiloidotiche

L’amiloidosi cardiaca è l’esempio tipico di cardiomiopatia infiltrativa. La diagnosi presuppone un alto indice di sospetto. Nella pratica clinica le cause più frequenti di amiloidosi sistemica sono: amiloidosi AL (secondaria alla deposizione di catene leggere libere circolanti delle immunoglobuline nel contesto di discrasia plasmocellulare), amiloidosi da deposizione di transtiretina mutata (amiloidosi ereditaria ATTR) e da deposizione di transtiretina nativa, “wild-type” (amiloidosi senile). L’ecocardiogramma, la lettura integrata ECG-ecocardiogramma e la risonanza magnetica forniscono importanti elementi per il sospetto diagnostico. La diagnosi finale deve essere necessariamente eziologica per poter orientare al meglio le strategie terapeutiche. L’amiloidosi ereditaria da mutazione della transtiretina (ATTRm) ha una espressione clinica prevalentemente neurologica. L’interessamento cardiaco è relativamente frequente (soprattutto nelle mutazioni diverse dalla Val30Met), ma è in genere successivo all’espressione del fenotipo neurologico. Se la cronologia di espressione dei due fenotipi si inverte, la probabilità di mancare la diagnosi di ATTRm è elevata. Nella realtà più del 10% dei pazienti affetti da ATTRm ha una espressione fenotipica prevalentemente o esclusivamente cardiologica. Questo sottogruppo si caratterizza per una netta prevalenza del sesso maschile, per una diagnosi in età più avanzata e per una frequenza particolarmente elevata della mutazione Ile68Leu. La consapevolezza dell’esistenza di queste forme di ATTRm è essenziale per una diagnosi corretta, soprattutto in ambito cardiologico.

Valutazione dell'efficacia dell'elettrocatetere ventricolare sinistro quadripolare nella terapia di resincronizzazione cardiaca

La terapia di resincronizzazione cardiaca (CRT) si è imposta negli ultimi dieci anni come l'alternativa migliore all'approccio farmacologico primario nella cura allo scompenso cardiaco: la stimolazione biventricolare utilizzando un elettrocatetere in ventricolo sinistro si è infatti rivelata uno dei metodi più efficaci per migliorare la dissincronia ventricolare negli stadi più avanzati anche nei pazienti che necessitano di una stimolazione continua e permanente come coloro che sono stati sottoposti ad ablazione del nodo AV. Esistono diversi punti irrisolti su cui la ricerca sta ancora lavorando per poter ottimizzare questa terapia, in particolar modo la percentuale (circa il 25-30%) dei pazienti in cui non si registrano miglioramenti dovuti alla terapia. Questa tesi, proposta dall'azienda St.Jude Medical Inc., segue la costruzione di un registro osservazionale per poter valutare l'efficacia della tecnologia quadripolare di ultima generazione. Dai dati emersi, la possibilità di programmare dieci diversi vettori di stimolazione contro i tre offerti dagli attuali dispositivi bipolari permette una maggiore libertà nel posizionamento dell'elettrocatetere ventricolare sinistro e una più semplice gestione delle complicanze come la stimolazione del nervo frenico (PNS), oltre a strutturare una terapia più specifica a seconda della risposta del paziente; inoltre la tecnologia quadripolare ha evidenziato migliori prestazioni in sede di impianto – tempi minori, più percentuali di successo e maggiori possibilità di posizionamento del catetere in zona ottimale con buoni valori di soglia – e meno interventi in seguito a complicanze. Il miglioramento della percentuale dei responder non è stato particolarmente significativo e necessita di ulteriori studi, ma è comunque incoraggiante e mostra che un numero più alto di configurazioni di stimolazione può essere una soluzione ottimale per la ricerca di una cura personalizzata, specialmente verso quei pazienti che durante l'impianto verrebbero esclusi per mancanza di stimolazioni corrette e possono, in questo modo, rientrare nella terapia fin dall'inizio.

Il Nilotinib nella terapia di prima linea della leucemia mieloide cronica

Background: Nilotinib is a potent and selective BCR-ABL inhibitor. The phase 3 ENESTnd trial demonstrated superior efficacy nilotinib vs imatinib, with higher and faster molecular responses. After 24 months, the rates of progression to accelerated-blastic phase (ABP) were 0.7% and 1.1% with nilotinib 300mg and 400mg BID, respectively, significantly lower compared to imatinib (4.2%). Nilotinib has been approved for the frontline treatment of Ph+ CML. With imatinib 400mg (IRIS trial), the rate of any event and of progression to ABP were higher during the first 3 years. Consequently, a confirmation of the durability of responses to nilotinib beyond 3 years is extremely important. Aims: To evaluate the response and the outcome of patients treated for 3 years with nilotinib 400mg BID as frontline therapy. Methods: A multicentre phase 2 trial was conducted by the GIMEMA CML WP (ClinicalTrials.gov.NCT00481052). Minimum 36-month follow-up data for all patients will be presented. Definitions: Major Molecular Response (MMR): BCR-ABL/ABL ratio <0,1%IS; Complete Molecular Response (CMR): undetectable transcript levels with ≥10,000 ABL transcripts; failures: according to the revised ELN recommendations; events: failures and treatment discontinuation for any reason. All the analysis has been made according to the intention-to-treat principle. Results: 73 patients enrolled: median age 51 years; 45% low, 41% intermediate and 14% high Sokal risk. The cumulative incidence of CCgR at 12 months was 100%. CCgR at each milestone: 78%, 96%, 96%, 95%, 92% at 3, 6, 12, 18 and 24 months, respectively. The overall estimated probability of MMR was 97%, while the rates of MMR at 3, 6, 12, 18 and 24 months were 52%, 66%, 85%, 81% and 82%, respectively. The overall estimated probability of CMR was 79%, while the rates of CMR at 12 and 24 months were 12% and 27%, respectively. No patient achieving a MMR progressed to AP. Only one patient progressed at 6 months to ABP and subsequently died (high Sokal risk, T315I mutation). Adverse events were mostly grade 1 or 2 and manageable with appropriate dose adaptations. During the first 12 months, the mean daily dose was 600-800mg in 74% of patients. The nilotinib last daily dose was as follows: 800mg in 46 (63%) patients, 600mg in 3 (4%) patients and 400mg in 18 (25%), 6 permanent discontinuations. Detail of discontinuation: 1 patient progressed to ABP; 3 patients had recurrent episodes of amylase and/or lipase increase (no pancreatitis); 1 patient had atrial fibrillation (unrelated to study drug) and 1 patient died after 32 months of mental deterioration and starvation (unrelated to study drug). Two patients are currently on imatinib second-line and 2 on dasatinib third-line. With a median follow-up of 39 months, the estimated probability of overall survival, progression-free survival and failure-free survival was 97%, the estimated probability of event-free survival was 91%. Conclusions: The rate of failures was very low during the first 3 years. Responses remain stable. The high rates of responses achieved during the first 12 months are being translated into optimal outcome for most of patients.

Campi elettromagnetici pulsanti nella terapia dell'artrosi del cane

The aim of this study is to evaluate the effects of the pulsed electromagnetic fields (PEMFS) on pain relief and functional capacity of dogs with osteoarthritis by which a single centre study prospective clinical trial. PEMFs are non ionized, athermic and time varying electromagnetic fields that has been successfully used for the treatment of osteoarthritis in human thanks to their chondroprotective, antinflammatory and analgesic property. 20 dogs were treated with PEMFs , 3 times per week for a total of 20 sessions.We found beneficial effects on pain relief and lameness in the absence of adverse effect. The decrease of pain impacted positively on the health-dogs related quality of life and the grade of satisfaction of their owner was very high. The benefits were obvious at half therapy and lasted for a medium long time. This is the first published report concerning PEMFs treatment on canine osteoarthtitis. The result of this study proves that PEMFs is a non –invasive remedy, lacking in adverse effect , easy to employ and useful for controlling pain and inflammation associated with osteoarthritis.

La nutrizione-idratazione artificiale è terapia? All'interfaccia tra scienza, diritto e bioetica, il fine vita in Italia, secondo una prospettiva di comunicazione della scienza post-accademica e Science&Technologies Studies (STS)

The question “artificial nutrition and hydration (ANH) is therapy or not?” is one of the key point of end-of-life issues in Italy, since it was (and it is also nowadays) a strategic and crucial point of the Italian Bioethics discussion about the last phases of human life: determining if ANH is therapy implies the possibility of being included in the list of treatments that could be mentioned for refusal within the living will document. But who is entitled to decide and judge if ANH is a therapy or not? Scientists? The Legislator? Judges? Patients? This issue at first sight seems just a matter of science, but at stake there is more than a scientific definition. According to several scholars, we are in the era of post-academic Science, in which Science broaden discussion, production, negotation and decision to other social groups that are not just the scientific communities. In this process, called co-production, on one hand scientific knowledge derives from the interaction between scientists and society at large. On the other hand, science is functional to co-production of social order. The continuous negotation on which science has to be used in social decisions is just the evidence of the mirroring negotation for different way to structure and interpret society. Thus, in the interaction between Science and Law, deciding what kind of Science could be suitable for a specific kind of Law, envisages a well defined idea of society behind this choice. I have analysed both the legislative path (still in progress) in the living will act production in Italy and Eluana Englaro’s judicial case (that somehow collapsed in the living will act negotiation), using official documents (hearings, texts of the official conference, committees comments and ruling texts) and interviewing key actors in the two processes from the science communication point of view (who talks in the name of science? Who defines what is a therapy? And how do they do?), finding support on the theoretical framework of the Science&Technologies Studies (S&TS).

Studio della funzione cardiaca e della massa ventricolare sinistra mediante ecocardiografia convenzionale e tissue doppler imaging in una popolazione pediatrica con malattia renale cronica in terapia conservativa e sostitutiva

Background: Cardiovascular disease (CVD) is a common cause of morbidity and mortality in childhood chronic kidney disease (CKD). Left ventricular hypertrophy (LVH) is known to be one of the earliest events in CVD development. Left ventricular diastolic function (DF) is thought to be also impaired in children with CKD. Tissue Doppler imaging (TDI) provide an accurate measure of DF and is less load dependent than conventional ECHO. Aim: To evaluate the LV mass and the DF in a population of children with CKD. Methods: 37 patients, median age: 10.4 (3.3-19.8); underlying renal disease: hypo/dysplasia (N=28), nephronophthisis (N=4), Alport (N=2), ARPKD (N=3), were analyzed. Thirty-eight percent of the patients were on stage 1-2 of CKD, 38% on stage 3, 16% on stage 4. Three patients were on dialysis. The most frequent factors related to CVD in CKD have been studied. LVH has been defined as a left ventricular mass index (LVMI) more than 35.7 g/h2,7. Results: Twenty-five patients (81%) had a LVH. LVMI and diastolic function index (E’/A’) were significantly related to the glomerular filtration rate (p<0.003 and p<0.004). Moreover the LVMI was correlated with the phosphorus and the hemoglobin level (p<0.0001 and p<0.004). LVH was present since the first stages of CKD (58% of patients were on stages 1-2). Early-diastolic myocardial velocity was reduced in 73% of our patients. We didn’t find any correlation between LVH and systemic hypertension. Conclusion: ECHO evaluation with TDI is suggested also in children prior to dialysis and with a normal blood pressure. If LVH is diagnosed, a periodic follow-up is necessary with the treatment of the modifiable risk factors (hypertension, disturbances of calcium, phosphorus and PTH, anemia ).